Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer

Jessica Tao, Pau Castel, Nina Radosevic-Robin, Moshe Elkabets, Neil Auricchio, Nicola Aceto, Gregory Weitsman, Paul Barber, Borivoj Vojnovic, Haley Ellis, Natasha Morse, Nerissa Therese Viola-Villegas, Ana Bosch, Dejan Juric, Saswati Hazra, Sharat Singh, Phillip Kim, Anna Bergamaschi, Shyamala Maheswaran, Tony NgFrédérique Penault-Llorca, Jason S. Lewis, Lisa A. Carey, Charles M. Perou, José Baselga, Maurizio Scaltriti

Research output: Contribution to journalArticle

Abstract

Both abundant epidermal growth factor receptor (EGFR or ErbB1) and high activity of the phosphatidylinositol 3-kinase (PI3K)-Akt pathway are common and therapeutically targeted in triple-negative breast cancer (TNBC). However, activation of another EGFR family member [human epidermal growth factor receptor 3 (HER3) (or ErbB3)] may limit the antitumor effects of these drugs. We found that TNBC cell lines cultured with the EGFR or HER3 ligand EGF or heregulin, respectively, and treated with either an Akt inhibitor (GDC- 0068) or a PI3K inhibitor (GDC-0941) had increased abundance and phosphorylation of HER3. The phosphorylation of HER3 and EGFR in response to these treatments was reduced by the addition of a dual EGFR and HER3 inhibitor (MEHD7945A). MEHD7945A also decreased the phosphorylation (and activation) of EGFR and HER3 and the phosphorylation of downstream targets that occurred in response to the combination of EGFR ligands and PI3K-Akt pathway inhibitors. In culture, inhibition of the PI3K-Akt pathway combined with either MEHD7945A or knockdown of HER3 decreased cell proliferation compared with inhibition of the PI3K-Akt pathway alone. Combining either GDC-0068 orGDC-0941 with MEHD7945A inhibited the growth of xenografts derived from TNBC cell lines or from TNBC patient tumors, and this combination treatment was also more effective thancombining eitherGDC-0068 orGDC-0941 with cetuximab, anEGFR-targeted antibody.After therapy with EGFR-targeted antibodies, some patients had residual tumors with increased HER3 abundance and EGFR/HER3 dimerization (an activating interaction). Thus, we propose that concomitant blockade of EGFR, HER3, and the PI3K-Akt pathway in TNBC should be investigated in the clinical setting.

Original languageEnglish (US)
Article numberra29
JournalScience signaling
Volume7
Issue number318
DOIs
StatePublished - Mar 25 2014
Externally publishedYes

Fingerprint

Phosphatidylinositol 3-Kinase
Triple Negative Breast Neoplasms
Epidermal Growth Factor Receptor
Phosphorylation
Tumors
Chemical activation
Cells
Neuregulin-1
Ligands
Cell Line
Dimerization
Antibodies
Residual Neoplasm
Cell proliferation
Epidermal Growth Factor
Heterografts
Antineoplastic Agents
Therapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. / Tao, Jessica; Castel, Pau; Radosevic-Robin, Nina; Elkabets, Moshe; Auricchio, Neil; Aceto, Nicola; Weitsman, Gregory; Barber, Paul; Vojnovic, Borivoj; Ellis, Haley; Morse, Natasha; Viola-Villegas, Nerissa Therese; Bosch, Ana; Juric, Dejan; Hazra, Saswati; Singh, Sharat; Kim, Phillip; Bergamaschi, Anna; Maheswaran, Shyamala; Ng, Tony; Penault-Llorca, Frédérique; Lewis, Jason S.; Carey, Lisa A.; Perou, Charles M.; Baselga, José; Scaltriti, Maurizio.

In: Science signaling, Vol. 7, No. 318, ra29, 25.03.2014.

Research output: Contribution to journalArticle

Tao, J, Castel, P, Radosevic-Robin, N, Elkabets, M, Auricchio, N, Aceto, N, Weitsman, G, Barber, P, Vojnovic, B, Ellis, H, Morse, N, Viola-Villegas, NT, Bosch, A, Juric, D, Hazra, S, Singh, S, Kim, P, Bergamaschi, A, Maheswaran, S, Ng, T, Penault-Llorca, F, Lewis, JS, Carey, LA, Perou, CM, Baselga, J & Scaltriti, M 2014, 'Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer', Science signaling, vol. 7, no. 318, ra29. https://doi.org/10.1126/scisignal.2005125
Tao, Jessica ; Castel, Pau ; Radosevic-Robin, Nina ; Elkabets, Moshe ; Auricchio, Neil ; Aceto, Nicola ; Weitsman, Gregory ; Barber, Paul ; Vojnovic, Borivoj ; Ellis, Haley ; Morse, Natasha ; Viola-Villegas, Nerissa Therese ; Bosch, Ana ; Juric, Dejan ; Hazra, Saswati ; Singh, Sharat ; Kim, Phillip ; Bergamaschi, Anna ; Maheswaran, Shyamala ; Ng, Tony ; Penault-Llorca, Frédérique ; Lewis, Jason S. ; Carey, Lisa A. ; Perou, Charles M. ; Baselga, José ; Scaltriti, Maurizio. / Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. In: Science signaling. 2014 ; Vol. 7, No. 318.
@article{a392bab038604369ab82d0365da7e44b,
title = "Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer",
abstract = "Both abundant epidermal growth factor receptor (EGFR or ErbB1) and high activity of the phosphatidylinositol 3-kinase (PI3K)-Akt pathway are common and therapeutically targeted in triple-negative breast cancer (TNBC). However, activation of another EGFR family member [human epidermal growth factor receptor 3 (HER3) (or ErbB3)] may limit the antitumor effects of these drugs. We found that TNBC cell lines cultured with the EGFR or HER3 ligand EGF or heregulin, respectively, and treated with either an Akt inhibitor (GDC- 0068) or a PI3K inhibitor (GDC-0941) had increased abundance and phosphorylation of HER3. The phosphorylation of HER3 and EGFR in response to these treatments was reduced by the addition of a dual EGFR and HER3 inhibitor (MEHD7945A). MEHD7945A also decreased the phosphorylation (and activation) of EGFR and HER3 and the phosphorylation of downstream targets that occurred in response to the combination of EGFR ligands and PI3K-Akt pathway inhibitors. In culture, inhibition of the PI3K-Akt pathway combined with either MEHD7945A or knockdown of HER3 decreased cell proliferation compared with inhibition of the PI3K-Akt pathway alone. Combining either GDC-0068 orGDC-0941 with MEHD7945A inhibited the growth of xenografts derived from TNBC cell lines or from TNBC patient tumors, and this combination treatment was also more effective thancombining eitherGDC-0068 orGDC-0941 with cetuximab, anEGFR-targeted antibody.After therapy with EGFR-targeted antibodies, some patients had residual tumors with increased HER3 abundance and EGFR/HER3 dimerization (an activating interaction). Thus, we propose that concomitant blockade of EGFR, HER3, and the PI3K-Akt pathway in TNBC should be investigated in the clinical setting.",
author = "Jessica Tao and Pau Castel and Nina Radosevic-Robin and Moshe Elkabets and Neil Auricchio and Nicola Aceto and Gregory Weitsman and Paul Barber and Borivoj Vojnovic and Haley Ellis and Natasha Morse and Viola-Villegas, {Nerissa Therese} and Ana Bosch and Dejan Juric and Saswati Hazra and Sharat Singh and Phillip Kim and Anna Bergamaschi and Shyamala Maheswaran and Tony Ng and Fr{\'e}d{\'e}rique Penault-Llorca and Lewis, {Jason S.} and Carey, {Lisa A.} and Perou, {Charles M.} and Jos{\'e} Baselga and Maurizio Scaltriti",
year = "2014",
month = "3",
day = "25",
doi = "10.1126/scisignal.2005125",
language = "English (US)",
volume = "7",
journal = "Science Signaling",
issn = "1937-9145",
publisher = "American Association for the Advancement of Science",
number = "318",

}

TY - JOUR

T1 - Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer

AU - Tao, Jessica

AU - Castel, Pau

AU - Radosevic-Robin, Nina

AU - Elkabets, Moshe

AU - Auricchio, Neil

AU - Aceto, Nicola

AU - Weitsman, Gregory

AU - Barber, Paul

AU - Vojnovic, Borivoj

AU - Ellis, Haley

AU - Morse, Natasha

AU - Viola-Villegas, Nerissa Therese

AU - Bosch, Ana

AU - Juric, Dejan

AU - Hazra, Saswati

AU - Singh, Sharat

AU - Kim, Phillip

AU - Bergamaschi, Anna

AU - Maheswaran, Shyamala

AU - Ng, Tony

AU - Penault-Llorca, Frédérique

AU - Lewis, Jason S.

AU - Carey, Lisa A.

AU - Perou, Charles M.

AU - Baselga, José

AU - Scaltriti, Maurizio

PY - 2014/3/25

Y1 - 2014/3/25

N2 - Both abundant epidermal growth factor receptor (EGFR or ErbB1) and high activity of the phosphatidylinositol 3-kinase (PI3K)-Akt pathway are common and therapeutically targeted in triple-negative breast cancer (TNBC). However, activation of another EGFR family member [human epidermal growth factor receptor 3 (HER3) (or ErbB3)] may limit the antitumor effects of these drugs. We found that TNBC cell lines cultured with the EGFR or HER3 ligand EGF or heregulin, respectively, and treated with either an Akt inhibitor (GDC- 0068) or a PI3K inhibitor (GDC-0941) had increased abundance and phosphorylation of HER3. The phosphorylation of HER3 and EGFR in response to these treatments was reduced by the addition of a dual EGFR and HER3 inhibitor (MEHD7945A). MEHD7945A also decreased the phosphorylation (and activation) of EGFR and HER3 and the phosphorylation of downstream targets that occurred in response to the combination of EGFR ligands and PI3K-Akt pathway inhibitors. In culture, inhibition of the PI3K-Akt pathway combined with either MEHD7945A or knockdown of HER3 decreased cell proliferation compared with inhibition of the PI3K-Akt pathway alone. Combining either GDC-0068 orGDC-0941 with MEHD7945A inhibited the growth of xenografts derived from TNBC cell lines or from TNBC patient tumors, and this combination treatment was also more effective thancombining eitherGDC-0068 orGDC-0941 with cetuximab, anEGFR-targeted antibody.After therapy with EGFR-targeted antibodies, some patients had residual tumors with increased HER3 abundance and EGFR/HER3 dimerization (an activating interaction). Thus, we propose that concomitant blockade of EGFR, HER3, and the PI3K-Akt pathway in TNBC should be investigated in the clinical setting.

AB - Both abundant epidermal growth factor receptor (EGFR or ErbB1) and high activity of the phosphatidylinositol 3-kinase (PI3K)-Akt pathway are common and therapeutically targeted in triple-negative breast cancer (TNBC). However, activation of another EGFR family member [human epidermal growth factor receptor 3 (HER3) (or ErbB3)] may limit the antitumor effects of these drugs. We found that TNBC cell lines cultured with the EGFR or HER3 ligand EGF or heregulin, respectively, and treated with either an Akt inhibitor (GDC- 0068) or a PI3K inhibitor (GDC-0941) had increased abundance and phosphorylation of HER3. The phosphorylation of HER3 and EGFR in response to these treatments was reduced by the addition of a dual EGFR and HER3 inhibitor (MEHD7945A). MEHD7945A also decreased the phosphorylation (and activation) of EGFR and HER3 and the phosphorylation of downstream targets that occurred in response to the combination of EGFR ligands and PI3K-Akt pathway inhibitors. In culture, inhibition of the PI3K-Akt pathway combined with either MEHD7945A or knockdown of HER3 decreased cell proliferation compared with inhibition of the PI3K-Akt pathway alone. Combining either GDC-0068 orGDC-0941 with MEHD7945A inhibited the growth of xenografts derived from TNBC cell lines or from TNBC patient tumors, and this combination treatment was also more effective thancombining eitherGDC-0068 orGDC-0941 with cetuximab, anEGFR-targeted antibody.After therapy with EGFR-targeted antibodies, some patients had residual tumors with increased HER3 abundance and EGFR/HER3 dimerization (an activating interaction). Thus, we propose that concomitant blockade of EGFR, HER3, and the PI3K-Akt pathway in TNBC should be investigated in the clinical setting.

UR - http://www.scopus.com/inward/record.url?scp=84897133359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897133359&partnerID=8YFLogxK

U2 - 10.1126/scisignal.2005125

DO - 10.1126/scisignal.2005125

M3 - Article

C2 - 24667376

AN - SCOPUS:84897133359

VL - 7

JO - Science Signaling

JF - Science Signaling

SN - 1937-9145

IS - 318

M1 - ra29

ER -